The FDA approved the prefilled syringe version of our medicine to treat wet age-related macular degeneration, diabetic macular edema and macular edema following retinal vein occlusion. Together, these three retinal conditions affect around 3 million people in the U.S. and are among the leading causes of vision loss. The prefilled syringe is designed to provide retina specialists a ready-to-use option for simpler administration. Learn more: http://spr.ly/60489pado
Congratulations. More options!
That's fantastic news, Genentech! The FDA approval of the prefilled syringe for treating these critical conditions is a significant advancement. Simplifying administration can make a real difference for patients and healthcare providers alike. 👁️💉 #MedicalInnovation #VisionCare
Yes Sir!!! More options for Physcians and of course, our patients! 💪🏽💪🏽
Genuine Leadership | Project & Program Management | Business Integration | Medical Devices | Combination Devices | Pharmaceuticals | Fostering Teamwork | New Product Development | Risk Management | Budgeting | Resourcing
1moI'm a huge proponent of drug delivery devices. My experience in new product development with these valuable combination devices has been overwhelmingly positive - for the patient as well as the drug company. Not only do these pre-filled syringes, autoinjectors, infussors, and on-body drug delivery devices make it easier to ensure proper dosing, they can: 1) Lower the overall cost of care by eliminating costly visits to their HCP. 2) Improve adherence to the patient's dosing regimen. and 3) Reduce the overall impact on the environment by eliminating/reducing physical visits to an HCP I look forward to applying my skills with combination drug delivery devices, as I have done while working for Biogen and Alexion Pharmaceuticals, Inc. (now part of AstraZeneca) in my recent past. Bottom line: there is still a lot of innovation needed with these combination devices. Opportunities abound for leveraging wireless communication (e.g. Bluetooth), dose confirmation, variable-dose control, and viscosity-compensating algorithms, just to name a few. I look forward to seeing more innovative solutions from companies such as BD, Ypsomed AG, West Pharmaceutical Services, ApiJect Systems and others. #innovation #pharma #medtech #biotech